Yazarlar : Schmid A, Friess D, Mansouri Taleghani B et al

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/role-plerixafor-autologous-stem-cell-mobilization-vinorelbine-chemotherapy-and-g-csf-patients-myelom?tsid=5

Konu : Myelom

Literatür İçeriği :  ABSTRACT Current practice in Switzerland for the mobilization of autologous stem cells in myeloma patients is combining vinorelbine chemotherapy and G-CSF cytokine stimulation. We prospectively investigated adding intravenous plerixafor to the vinorelbine/G-CSF combination (VGP), and compared it to vinorelbine/plerixafor (VP) and G-CSF/plerixafor (GP) combinations. In a final cohort (VP-late), plerixafor was given on the first day of CD34+ cells rising>15'000/ml peripheral blood. Four consecutive cohorts of ten myeloma patients were studied. We observed that intravenously administered plerixafor can be safely combined with vinorelbine/G-CSF. VGP was superior in mobilizing peripheral stem and progenitor cells compared to the three double combinations (VP, GP and VP-late), and GP mobilized better than VP. Our data indicate that the triple combination of vinorelbine, G-CSF and plerixafor is an efficient strategy to collect autologous CD34+ cells, with G-CSF contributing predominantly in this concept. Plerixafor can be safely added to G-CSF and/or to vinorelbine chemotherapy.

Literatür Arşivi